Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Strong Conflict of Interest Policies are not Associated with Decreased Industry Payments to Academic Urology Departments.

Bandari J, Pace NM, Lee AJ, Ayyash OM, Yecies TS, Jacobs BL, Davies BJ.

Urology. 2020 Mar 9. pii: S0090-4295(20)30258-2. doi: 10.1016/j.urology.2020.02.022. [Epub ahead of print]

PMID:
32165276
2.

Decrease in Urologic Discharge Opioid Prescribing after Mandatory Query of Statewide Prescription Drug Monitoring Program.

Myrga JM, Macleod LC, Bandari J, Jacobs BL, Davies BJ.

Urology. 2020 Feb 13. pii: S0090-4295(20)30164-3. doi: 10.1016/j.urology.2020.02.002. [Epub ahead of print]

PMID:
32061826
3.

Increasing use of positron emission tomography among medicare beneficiaries undergoing radical cystectomy.

Maganty A, Turner RM 2nd, Yabes JG, Heron DE, Gingrich JR, Davies BJ, Jacobs BL.

Eur J Cancer Care (Engl). 2020 Feb 5:e13230. doi: 10.1111/ecc.13230. [Epub ahead of print]

PMID:
32026559
4.

Gender Gap in Industry Relationships and Scholarly Impact Among Academic Urologists in the United States.

Pace NM, Maganty A, Siripong N, Lee AJ, Huang D, Bandari J, Jacobs BL, Davies BJ.

Urology. 2020 Jan 29. pii: S0090-4295(20)30101-1. doi: 10.1016/j.urology.2020.01.022. [Epub ahead of print]

PMID:
32006547
5.

Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer.

Macleod LC, Fam MM, Yabes JG, Hale NE, Turner RM 2nd, Lopa SH, Gingrich JR, Borza T, Skolarus TA, Davies BJ, Jacobs BL.

Clin Genitourin Cancer. 2019 Dec 14. pii: S1558-7673(19)30384-2. doi: 10.1016/j.clgc.2019.12.011. [Epub ahead of print]

PMID:
31917172
6.

Importance and vulnerability of the world's water towers.

Immerzeel WW, Lutz AF, Andrade M, Bahl A, Biemans H, Bolch T, Hyde S, Brumby S, Davies BJ, Elmore AC, Emmer A, Feng M, Fernández A, Haritashya U, Kargel JS, Koppes M, Kraaijenbrink PDA, Kulkarni AV, Mayewski PA, Nepal S, Pacheco P, Painter TH, Pellicciotti F, Rajaram H, Rupper S, Sinisalo A, Shrestha AB, Viviroli D, Wada Y, Xiao C, Yao T, Baillie JEM.

Nature. 2020 Jan;577(7790):364-369. doi: 10.1038/s41586-019-1822-y. Epub 2019 Dec 9.

PMID:
31816624
7.

Editorial Comment.

Pekala KR, Davies BJ, Jacobs BL.

J Urol. 2020 Mar;203(3):551-552. doi: 10.1097/JU.0000000000000522.01. Epub 2019 Nov 26. No abstract available.

PMID:
31769721
8.

Opium Wars to the Opioid Epidemic: The Same Narcotics Cause Addiction and Kill.

Yu M, Davies BJ.

Eur Urol. 2020 Jan;77(1):76-77. doi: 10.1016/j.eururo.2019.10.006. Epub 2019 Nov 8. No abstract available.

PMID:
31711720
9.

Evaluating the Effectiveness of an Online Journal Club: Experience from the International Urology Journal Club.

Thangasamy IA, Loeb S, Sathianathen NJ, Leveridge M, Stork B, Davies BJ, Woo HH.

Eur Urol Focus. 2019 Oct 31. pii: S2405-4569(19)30312-8. doi: 10.1016/j.euf.2019.10.006. [Epub ahead of print]

PMID:
31679867
10.

The Safety and Short-term Outcomes of Leukocyte Depleted Autologous Transfusions During Radical Cystectomy.

Myrga JM, Ayyash OM, Bandari J, Fam MM, Macleod LC, Jacobs BL, Davies BJ.

Urology. 2020 Jan;135:106-110. doi: 10.1016/j.urology.2019.08.056. Epub 2019 Oct 16.

PMID:
31626857
11.

Editorial Comment.

Yu M, Davies BJ, Jacobs BL.

J Urol. 2020 Jan;203(1):150. doi: 10.1097/01.JU.0000602704.44846.e4. Epub 2019 Oct 3. No abstract available.

PMID:
31580767
12.

The Shrinking Grey Zone of Postoperative Narcotics in the Midst of the Opioid Crisis: The No-opioid Urologist.

Pekala KR, Jacobs BL, Davies BJ.

Eur Urol Focus. 2019 Sep 25. pii: S2405-4569(19)30272-X. doi: 10.1016/j.euf.2019.08.014. [Epub ahead of print]

PMID:
31563546
13.

Implications of Cystectomy Travel Distance for Hospital Readmission and Survival.

Hale NE, Macleod LC, Yabes JG, Turner RM 2nd, Fam MM, Gingrich JR, Skolarus TA, Borza T, Sabik LM, Davies BJ, Jacobs BL.

Clin Genitourin Cancer. 2019 Dec;17(6):e1171-e1180. doi: 10.1016/j.clgc.2019.08.005. Epub 2019 Aug 20.

PMID:
31543443
14.

Don't Be a Luddite: Urologists Benefit from Social Media.

Bayne CE, Davies BJ.

Eur Urol Focus. 2019 Sep 4. pii: S2405-4569(19)30273-1. doi: 10.1016/j.euf.2019.08.015. [Epub ahead of print]

PMID:
31494094
15.

How to Use Social Media in Urologic Practice.

Shah AA, Davies BJ.

Eur Urol Focus. 2019 Aug 19. pii: S2405-4569(19)30209-3. doi: 10.1016/j.euf.2019.07.008. [Epub ahead of print]

PMID:
31439507
16.

Under Treatment of Prostate Cancer in Rural Locations.

Maganty A, Sabik LM, Sun Z, Eom KY, Li J, Davies BJ, Jacobs BL.

J Urol. 2020 Jan;203(1):108-114. doi: 10.1097/JU.0000000000000500. Epub 2019 Aug 20.

17.

Evaluation of the Risks and Benefits of Computed Tomography Urography for Assessment of Gross Hematuria.

Yecies T, Bandari J, Macleod L, Fam M, Davies BJ, Jacobs BL.

Urology. 2019 Nov;133:40-45. doi: 10.1016/j.urology.2019.04.055. Epub 2019 Jun 27. Review.

PMID:
31255539
18.

A Radical Proposition: Opioid-sparing Prostatectomy.

Theisen KM, Davies BJ.

Eur Urol Focus. 2020 Mar 15;6(2):215-217. doi: 10.1016/j.euf.2019.06.011. Epub 2019 Jun 21.

PMID:
31231009
19.

E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer.

Li F, Pascal LE, Stolz DB, Wang K, Zhou Y, Chen W, Xu Y, Chen Y, Dhir R, Parwani AV, Nelson JB, DeFranco DB, Yoshimura N, Balasubramani GK, Gingrich JR, Maranchie JK, Jacobs BL, Davies BJ, Hrebinko RL, Bigley JD, McBride D, Guo P, He D, Wang Z.

Prostate. 2019 Aug;79(11):1226-1237. doi: 10.1002/pros.23806. Epub 2019 Jun 18.

PMID:
31212363
20.

The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.

Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF.

Eur Urol. 2019 Sep;76(3):268-272. doi: 10.1016/j.eururo.2019.05.013. Epub 2019 May 23.

PMID:
31128968
21.

Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.

Macleod LC, Yabes JG, Yu M, Fam MM, Hale NE, Turner RM 2nd, Lopa SH, Gingrich JR, Borza T, Skolarus TA, Davies BJ, Jacobs BL.

Urol Oncol. 2019 Jul;37(7):462-469. doi: 10.1016/j.urolonc.2019.04.006. Epub 2019 Apr 30.

PMID:
31053530
22.

Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.

Macleod LC, Yabes JG, Fam MM, Bandari J, Yu M, Maganty A, Furlan A, Filson CP, Davies BJ, Jacobs BL.

Eur Urol Focus. 2020 Mar 15;6(2):242-248. doi: 10.1016/j.euf.2019.04.008. Epub 2019 Apr 25.

PMID:
31031042
23.

Downstream Studies Following the Use of Bone Scan in the Staging of Muscle-invasive Bladder Cancer.

Maganty A, Turner RM 2nd, Yabes JG, Davies BJ, Heron DE, Jacobs BL.

Urology. 2019 Jul;129:74-78. doi: 10.1016/j.urology.2019.04.009. Epub 2019 Apr 18.

PMID:
31005656
24.

Increasing Utilization of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.

Fam MM, Yabes JG, Macleod LC, Bandari J, Turner RM 2nd, Lopa SH, Furlan A, Filson CP, Davies BJ, Jacobs BL.

Urology. 2019 Aug;130:99-105. doi: 10.1016/j.urology.2019.02.037. Epub 2019 Mar 30.

PMID:
30940480
25.

Editorial Comment.

Bandari J, Maganty A, Davies BJ.

Urology. 2019 Feb;124:125-126. doi: 10.1016/j.urology.2018.07.056. No abstract available.

PMID:
30784708
26.

Palliative care use amongst patients with bladder cancer.

Hugar LA, Lopa SH, Yabes JG, Yu JA, Turner RM 2nd, Fam MM, MacLeod LC, Davies BJ, Smith AB, Jacobs BL.

BJU Int. 2019 Jun;123(6):968-975. doi: 10.1111/bju.14708. Epub 2019 Mar 12.

PMID:
30758125
27.

Small cell bladder cancer: should we consider prophylactic cranial irradiation?

Morgan TN, Turner RM II, Baptiste J, Lyon TD, Maranchie JK, Hrebinko RL, Davies BJ, Gingrich JR, Jacobs BL.

Int Braz J Urol. 2019 Mar-Apr;45(2):299-305. doi: 10.1590/S1677-5538.IBJU.2018.0242.

28.

The American Opioid Crisis: The Inexorable March to Death and Addiction.

Theisen K, Davies BJ.

Eur Urol. 2019 Feb;75(2):219-220. doi: 10.1016/j.eururo.2018.10.051. Epub 2018 Nov 12. No abstract available.

PMID:
30442426
29.

Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries With Bladder Cancer: A SEER-Medicare Analysis.

Hugar LA, Yabes JG, Turner RM 2nd, Fam MM, Appleman LJ, Davies BJ, Jacobs BL.

Urology. 2019 Feb;124:191-197. doi: 10.1016/j.urology.2018.11.001. Epub 2018 Nov 10.

PMID:
30423302
30.

Concentration of Opioid-Related Industry Payments in Opioid Crisis Areas.

Lee AJ, Bandari J, Macleod LC, Davies BJ, Jacobs BL.

J Gen Intern Med. 2019 Feb;34(2):187-189. doi: 10.1007/s11606-018-4700-7. No abstract available.

31.

Extreme Price Variation for Generic Benign Prostatic Hyperplasia Medications.

Theisen KM, Park SY, Jeong K, Macleod LC, Bandari J, Ayyash O, Odisho AY, Jacobs BL, Davies BJ.

Urology. 2019 Feb;124:223-228. doi: 10.1016/j.urology.2018.10.020. Epub 2018 Oct 23.

PMID:
30359708
32.

Erratum to expanded criteria for active surveillance in prostate cancer: a review of the current data.

Jones C, Fam MM, Davies BJ.

Transl Androl Urol. 2018 Aug;7(4):764. doi: 10.21037/tau.2018.08.05.

33.

Excessive Opioid Prescribing After Major Urologic Procedures.

Theisen KM, Myrga JM, Hale N, Cochran G, Sewall C, Macleod LC, Jacobs BL, Davies BJ.

Urology. 2019 Jan;123:101-107. doi: 10.1016/j.urology.2018.06.057. Epub 2018 Aug 24.

PMID:
30149041
34.

Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Guérin.

Bandari J, Maganty A, MacLeod LC, Davies BJ.

Eur Urol Focus. 2018 Jul;4(4):481-484. doi: 10.1016/j.euf.2018.06.018. Epub 2018 Jul 11. Review.

PMID:
30005997
35.

Effect of multimodal analgesia with paravertebral blocks on biochemical recurrence in men undergoing open radical prostatectomy.

Macleod LC, Turner RM 2nd, Lopa S, Hugar LA, Davies BJ, Ben-David B, Chelly JE, Jacobs BL, Nelson JB.

Urol Oncol. 2018 Aug;36(8):364.e9-364.e14. doi: 10.1016/j.urolonc.2018.05.016. Epub 2018 Jun 7.

PMID:
29887239
36.

Expanded criteria for active surveillance in prostate cancer: a review of the current data.

Jones C, Fam MM, Davies BJ.

Transl Androl Urol. 2018 Apr;7(2):221-227. doi: 10.21037/tau.2017.08.23. Review. Erratum in: Transl Androl Urol. 2018 Aug;7(4):764.

37.

Active surveillance for prostate cancer.

Dall'Era MA, Davies BJ, Eggener S.

Transl Androl Urol. 2018 Apr;7(2):195-196. doi: 10.21037/tau.2018.03.03. No abstract available.

38.

The comparative effectiveness of quadratus lumborum blocks and paravertebral blocks in radical cystectomy patients.

Lee AJ, Yabes JG, Hale N, Hrebinko RL, Gingrich JR, Maranchie JK, Fam MM, Turner I I RM, Davies BJ, Ben-David B, Jacobs BL.

Can J Urol. 2018 Apr;25(2):9255-9261..

PMID:
29680003
39.

Evaluation of Vasectomy Trends in the United States.

Ostrowski KA, Holt SK, Haynes B, Davies BJ, Fuchs EF, Walsh TJ.

Urology. 2018 Aug;118:76-79. doi: 10.1016/j.urology.2018.03.016. Epub 2018 Mar 22.

PMID:
29578040
40.

Physician Reimbursement for Prostate Biopsies Falls as Procedures Shift From Offices to Facilities.

Henry MA, Howard DH, Davies BJ, Filson CP.

Urology. 2018 May;115:96-101. doi: 10.1016/j.urology.2018.02.008. Epub 2018 Mar 12.

PMID:
29545049
41.

Marketing and Testosterone Treatment in the USA: A Systematic Review.

Bandari J, Ayyash OM, Emery SL, Wessel CB, Davies BJ.

Eur Urol Focus. 2017 Oct;3(4-5):395-402. doi: 10.1016/j.euf.2017.10.016. Epub 2017 Nov 23. Review.

PMID:
29174614
42.

Evidence-Based Reporting: A Method to Optimize Prostate MRI Communications With Referring Physicians.

Magnetta MJ, Donovan AL, Jacobs BL, Davies BJ, Furlan A.

AJR Am J Roentgenol. 2018 Jan;210(1):108-112. doi: 10.2214/AJR.17.18260. Epub 2017 Nov 1.

PMID:
29091009
43.

The use of intraoperative cell salvage in urologic oncology.

Ferroni MC, Correa AF, Lyon TD, Davies BJ, Ost MC.

Rev Urol. 2017;19(2):89-96.

44.

Preoperative immunonutrition prior to radical cystectomy: a pilot study.

Lyon TD, Turner I I RM, McBride D, Wang L, Gingrich JR, Hrebinko RL, Jacobs BL, Davies BJ, Tarin TV.

Can J Urol. 2017 Aug;24(4):8895-8901.

PMID:
28832307
45.

Chipping away at the body politic one study at a time: the case for more 'unprofessional' online content.

Bayne CE, Davies BJ.

BJU Int. 2017 Nov;120(5):609-610. doi: 10.1111/bju.13986. Epub 2017 Sep 5. No abstract available.

46.

The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.

Bandari J, Ayyash OM, Turner RM 2nd, Jacobs BL, Davies BJ.

Cancer. 2017 Nov 15;123(22):4356-4362. doi: 10.1002/cncr.30914. Epub 2017 Jul 27.

47.

Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines.

Henry MA, Howard DH, Davies BJ, Filson CP.

J Urol. 2017 Nov;198(5):1046-1053. doi: 10.1016/j.juro.2017.05.008. Epub 2017 May 6.

PMID:
28487099
48.

Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer.

Davies BJ, Hwang TJ, Kesselheim AS.

N Engl J Med. 2017 Apr 13;376(15):1401-1403. doi: 10.1056/NEJMp1615697. No abstract available.

PMID:
28402764
49.

Variations in Preoperative Use of Bone Scan Among Medicare Beneficiaries Undergoing Radical Cystectomy.

Turner RM 2nd, Yabes JG, Davies BJ, Heron DE, Jacobs BL.

Urology. 2017 May;103:84-90. doi: 10.1016/j.urology.2017.02.028. Epub 2017 Feb 24.

50.

The Relationship of Industry Payments to Prescribing Behavior: A Study of Degarelix and Denosumab.

Bandari J, Turner RM 2nd, Jacobs BL, Canes D, Moinzadeh A, Davies BJ.

Urol Pract. 2017 Jan;4(1):14-20. doi: 10.1016/j.urpr.2016.03.007.

Supplemental Content

Loading ...
Support Center